Skip to main content
PMC home page
British Journal of Cancer logoLink to British Journal of Cancer
. 1995 Oct;72(4):992–997. doi: 10.1038/bjc.1995.448

Continuous carboplatin infusion during 6 weeks' radiotherapy in locally inoperable non-small-cell lung cancer: a phase I and pharmacokinetic study.

H J Groen 1, A H van der Leest 1, E G de Vries 1, D R Uges 1, B G Szabó 1, N H Mulder 1
PMCID: PMC2034056  PMID: 7547255

Abstract

A phase I study was performed in 21 patients with previously untreated, locally inoperable, non-small-cell lung cancer (NSCLC) with ambulatory continuous carboplatin infusion together with continuous thoracic irradiation over 6 weeks. A dose range for carboplatin of 15 mg m-2 day-1 during the last 21 days (first level), during the last 31 days (second level), or during 6 weeks of the radiation period (third level) and thereafter 20 or 25 mg m-2 day-1 during 6 weeks of radiation (fourth and fifth level) was used. The total radiation dose was 60 Gy given as 2 Gy day-1 for 5 days week-1. The first three patients received radiotherapy without carboplatin. WHO grade III/IV leucopenia and thrombocytopenia occurred in the last two dose levels in two out of six and one out of six patients with 20 mg m-2 day-1 respectively, and in all three patients with 25 mg m-2 day-1 (dose-limiting toxicity). One local infection around the port and a subclavian vein thrombosis occurred. Radiation toxicity of the lung and oesophagus did not seem to be influenced by carboplatin treatment. Out of 21 patients one had a complete response (CR), ten partial response (PR), six stable disease (SD) and four progressive disease (PD). Total (TPt) and ultrafilterable plasma platinum (UPt) were measured in the last three dose levels with atomic absorption spectrophotometry with Zeeman correction. The mean (s.d.) level for TPt for 6 weeks at 15, 20 and 25 mg m-2 day-1 was 0.76 (0.15), 0.78 (0.19) and 0.90 (0.22) mg l-1 for UPt 0.10 (0.03), 0.12 (0.02) and 0.20 (0.03) mg l-1 respectively. TPt concentration levelled off after 3 weeks. The mean (s.d.) CLTB for UPt was 281 +/- 21 ml min-1 and correlated with glomerular filtration rate (r = 0.61, P = 0.03). As estimated with the sigmoid Emax model defined by the Hill equation the percentage reduction in platelets correlated with the area under the curve for UPt (r = 0.77). The maximum tolerable dose of carboplatin with concomitant continuous 60 Gy radiotherapy is 25 mg m-2 day-1; the recommended dose for phase II or III studies is 20 mg m-2 day-1 day for 6 weeks.

Full text

PDF
992

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Begg A. C., van der Kolk P. J., Emondt J., Bartelink H. Radiosensitization in vitro by cis-diammine (1,1-cyclobutanedicarboxylato) platinum(II) (carboplatin, JM8) and ethylenediammine-malonatoplatinum(II) (JM40). Radiother Oncol. 1987 Jun;9(2):157–165. doi: 10.1016/s0167-8140(87)80204-9. [DOI] [PubMed] [Google Scholar]
  2. Bonomi P. Brief overview of combination chemotherapy in non-small-cell lung cancer. Semin Oncol. 1986 Sep;13(3 Suppl 3):89–91. [PubMed] [Google Scholar]
  3. Bunn P. A., Jr Clinical experiences with carboplatin (paraplatin) in lung cancer. Semin Oncol. 1992 Feb;19(1 Suppl 2):1–11. [PubMed] [Google Scholar]
  4. Bunn P. A., Jr The expanding role of cisplatin in the treatment of non-small-cell lung cancer. Semin Oncol. 1989 Aug;16(4 Suppl 6):10–21. [PubMed] [Google Scholar]
  5. Cockcroft D. W., Gault M. H. Prediction of creatinine clearance from serum creatinine. Nephron. 1976;16(1):31–41. doi: 10.1159/000180580. [DOI] [PubMed] [Google Scholar]
  6. Collis C. H. A kinetic model for the pathogenesis of radiation lung damage. Int J Radiat Biol Relat Stud Phys Chem Med. 1982 Sep;42(3):253–263. doi: 10.1080/09553008214551181. [DOI] [PubMed] [Google Scholar]
  7. Collis C. H., Steel G. G. Dose-dependence of the time of appearance of lung damage in mice given thoracic irradiation. Int J Radiat Biol Relat Stud Phys Chem Med. 1982 Sep;42(3):245–252. doi: 10.1080/09553008214551171. [DOI] [PubMed] [Google Scholar]
  8. Coughlin C. T., Richmond R. C. Biologic and clinical developments of cisplatin combined with radiation: concepts, utility, projections for new trials, and the emergence of carboplatin. Semin Oncol. 1989 Aug;16(4 Suppl 6):31–43. [PubMed] [Google Scholar]
  9. Cox J. D., Azarnia N., Byhardt R. W., Shin K. H., Emami B., Pajak T. F. A randomized phase I/II trial of hyperfractionated radiation therapy with total doses of 60.0 Gy to 79.2 Gy: possible survival benefit with greater than or equal to 69.6 Gy in favorable patients with Radiation Therapy Oncology Group stage III non-small-cell lung carcinoma: report of Radiation Therapy Oncology Group 83-11. J Clin Oncol. 1990 Sep;8(9):1543–1555. doi: 10.1200/JCO.1990.8.9.1543. [DOI] [PubMed] [Google Scholar]
  10. Dillman R. O., Seagren S. L., Propert K. J., Guerra J., Eaton W. L., Perry M. C., Carey R. W., Frei E. F., 3rd, Green M. R. A randomized trial of induction chemotherapy plus high-dose radiation versus radiation alone in stage III non-small-cell lung cancer. N Engl J Med. 1990 Oct 4;323(14):940–945. doi: 10.1056/NEJM199010043231403. [DOI] [PubMed] [Google Scholar]
  11. Dosoretz D. E., Galmarini D., Rubenstein J. H., Katin M. J., Blitzer P. H., Salenius S. A., Dosani R. A., Rashid M., Mestas G., Hannan S. E. Local control in medically inoperable lung cancer: an analysis of its importance in outcome and factors determining the probability of tumor eradication. Int J Radiat Oncol Biol Phys. 1993 Oct 20;27(3):507–516. doi: 10.1016/0360-3016(93)90373-4. [DOI] [PubMed] [Google Scholar]
  12. Douple E. B., Richmond R. C., O'Hara J. A., Coughlin C. T. Carboplatin as a potentiator of radiation therapy. Cancer Treat Rev. 1985 Sep;12 (Suppl A):111–124. doi: 10.1016/0305-7372(85)90026-x. [DOI] [PubMed] [Google Scholar]
  13. Douple E. B., Richmond R. C. Radiosensitization of hypoxic tumor cells by cis- and trans-dichlorodiammineplatinum (II). Int J Radiat Oncol Biol Phys. 1979 Aug;5(8):1369–1372. doi: 10.1016/0360-3016(79)90672-2. [DOI] [PubMed] [Google Scholar]
  14. Egorin M. J., Reyno L. M., Canetta R. M., Jodrell D. I., Swenerton K. D., Pater J. L., Burroughs J. N., Novak M. J., Sridhara R. Modeling toxicity and response in carboplatin-based combination chemotherapy. Semin Oncol. 1994 Oct;21(5 Suppl 12):7–19. [PubMed] [Google Scholar]
  15. Egorin M. J., Van Echo D. A., Tipping S. J., Olman E. A., Whitacre M. Y., Thompson B. W., Aisner J. Pharmacokinetics and dosage reduction of cis-diammine(1,1-cyclobutanedicarboxylato)platinum in patients with impaired renal function. Cancer Res. 1984 Nov;44(11):5432–5438. [PubMed] [Google Scholar]
  16. Greidanus J., de Vries E. G., Nieweg M. B., de Langen Z. J., Willemse P. H. Evaluation of a totally implanted venous access port and portable pump in a continuous chemotherapy infusion schedule on an outpatient basis. Eur J Cancer Clin Oncol. 1987 Nov;23(11):1653–1657. doi: 10.1016/0277-5379(87)90445-7. [DOI] [PubMed] [Google Scholar]
  17. Kjaer M. Radiotherapy of squamous, adeno- and large cell carcinoma of the lung. Cancer Treat Rev. 1982 Mar;9(1):1–20. doi: 10.1016/s0305-7372(82)80002-9. [DOI] [PubMed] [Google Scholar]
  18. Knox R. J., Friedlos F., Lydall D. A., Roberts J. J. Mechanism of cytotoxicity of anticancer platinum drugs: evidence that cis-diamminedichloroplatinum(II) and cis-diammine-(1,1-cyclobutanedicarboxylato)platinum(II) differ only in the kinetics of their interaction with DNA. Cancer Res. 1986 Apr;46(4 Pt 2):1972–1979. [PubMed] [Google Scholar]
  19. Kreisman H., Ginsberg S., Propert K. J., Richards F., Graziano S., Green M. Carboplatin or iproplatin in advanced non-small cell lung cancer: a Cancer and Leukemia Group B Study. Cancer Treat Rep. 1987 Nov;71(11):1049–1052. [PubMed] [Google Scholar]
  20. Mattson K., Holsti L. R., Holsti P., Jakobsson M., Kajanti M., Liippo K., Mäntylä M., Niitamo-Korhonen S., Nikkanen V., Nordman E. Inoperable non-small cell lung cancer: radiation with or without chemotherapy. Eur J Cancer Clin Oncol. 1988 Mar;24(3):477–482. doi: 10.1016/s0277-5379(98)90020-7. [DOI] [PubMed] [Google Scholar]
  21. Micetich K. C., Barnes D., Erickson L. C. A comparative study of the cytotoxicity and DNA-damaging effects of cis-(diammino)(1,1-cyclobutanedicarboxylato)-platinum(II) and cis-diamminedichloroplatinum(II) on L1210 cells. Cancer Res. 1985 Sep;45(9):4043–4047. [PubMed] [Google Scholar]
  22. Morton R. F., Jett J. R., McGinnis W. L., Earle J. D., Therneau T. M., Krook J. E., Elliott T. E., Mailliard J. A., Nelimark R. A., Maksymiuk A. W. Thoracic radiation therapy alone compared with combined chemoradiotherapy for locally unresectable non-small cell lung cancer. A randomized, phase III trial. Ann Intern Med. 1991 Nov 1;115(9):681–686. doi: 10.7326/0003-4819-115-9-681. [DOI] [PubMed] [Google Scholar]
  23. Perez C. A., Pajak T. F., Rubin P., Simpson J. R., Mohiuddin M., Brady L. W., Perez-Tamayo R., Rotman M. Long-term observations of the patterns of failure in patients with unresectable non-oat cell carcinoma of the lung treated with definitive radiotherapy. Report by the Radiation Therapy Oncology Group. Cancer. 1987 Jun 1;59(11):1874–1881. doi: 10.1002/1097-0142(19870601)59:11<1874::aid-cncr2820591106>3.0.co;2-z. [DOI] [PubMed] [Google Scholar]
  24. Perez C. A., Stanley K., Grundy G., Hanson W., Rubin P., Kramer S., Brady L. W., Marks J. E., Perez-Tamayo R., Brown G. S. Impact of irradiation technique and tumor extent in tumor control and survival of patients with unresectable non-oat cell carcinoma of the lung: report by the Radiation Therapy Oncology Group. Cancer. 1982 Sep 15;50(6):1091–1099. doi: 10.1002/1097-0142(19820915)50:6<1091::aid-cncr2820500612>3.0.co;2-0. [DOI] [PubMed] [Google Scholar]
  25. Roed H., Vindeløv L. L., Christensen I. J., Spang-Thomsen M., Hansen H. H. The cytotoxic activity of cisplatin, carboplatin and teniposide alone and combined determined on four human small cell lung cancer cell lines by the clonogenic assay. Eur J Cancer Clin Oncol. 1988 Feb;24(2):247–253. doi: 10.1016/0277-5379(88)90261-1. [DOI] [PubMed] [Google Scholar]
  26. Rosiello R. A., Merrill W. W., Rockwell S., Carter D., Cooper J. A., Jr, Care S., Amento E. P. Radiation pneumonitis. Bronchoalveolar lavage assessment and modulation by a recombinant cytokine. Am Rev Respir Dis. 1993 Dec;148(6 Pt 1):1671–1676. doi: 10.1164/ajrccm/148.6_Pt_1.1671. [DOI] [PubMed] [Google Scholar]
  27. Salazar O. M., Rubin P., Brown J. C., Feldstein M. L., Keller B. E. The assessment of tumor response to irradiation of lung cancer: continuous versus split-course regimes. Int J Radiat Oncol Biol Phys. 1976 Nov-Dec;1(11-12):1107–1118. doi: 10.1016/0360-3016(76)90083-3. [DOI] [PubMed] [Google Scholar]
  28. Schaake-Koning C., Bartelink H., Adema B. H., Schuster-Uitterhoeve L., van Zandwijk N. Radiotherapy and cis-diammine dichloroplatinum (II) as a combined treatment modality for inoperable non-small cell lung cancer: a dose finding study. Int J Radiat Oncol Biol Phys. 1986 Mar;12(3):379–383. doi: 10.1016/0360-3016(86)90354-8. [DOI] [PubMed] [Google Scholar]
  29. Schaake-Koning C., van den Bogaert W., Dalesio O., Festen J., Hoogenhout J., van Houtte P., Kirkpatrick A., Koolen M., Maat B., Nijs A. Effects of concomitant cisplatin and radiotherapy on inoperable non-small-cell lung cancer. N Engl J Med. 1992 Feb 20;326(8):524–530. doi: 10.1056/NEJM199202203260805. [DOI] [PubMed] [Google Scholar]
  30. Skov K., MacPhail S. Interaction of platinum drugs with clinically relevant x-ray doses in mammalian cells: a comparison of cisplatin, carboplatin, iproplatin, and tetraplatin. Int J Radiat Oncol Biol Phys. 1991 Feb;20(2):221–225. doi: 10.1016/0360-3016(91)90094-k. [DOI] [PubMed] [Google Scholar]
  31. Sleijfer D. T., Smit E. F., Meijer S., Mulder N. H., Postmus P. E. Acute and cumulative effects of carboplatin on renal function. Br J Cancer. 1989 Jul;60(1):116–120. doi: 10.1038/bjc.1989.233. [DOI] [PMC free article] [PubMed] [Google Scholar]
  32. Smit E. F., Willemse P. H., Sleijfer D. T., Uges D. R., Postmus P. E., Meijer S., Terheggen P. M., Mulder N. H., de Vries E. G. Continuous infusion carboplatin on a 21-day schedule: a phase I and pharmacokinetic study. J Clin Oncol. 1991 Jan;9(1):100–110. doi: 10.1200/JCO.1991.9.1.100. [DOI] [PubMed] [Google Scholar]
  33. Soresi E., Clerici M., Grilli R., Borghini U., Zucali R., Leoni M., Botturi M., Vergari C., Luporini G., Scoccia S. A randomized clinical trial comparing radiation therapy v radiation therapy plus cis-dichlorodiammine platinum (II) in the treatment of locally advanced non-small cell lung cancer. Semin Oncol. 1988 Dec;15(6 Suppl 7):20–25. [PubMed] [Google Scholar]
  34. Tanabe M., Godat D., Kallman R. F. Effects of fractionated schedules of irradiation combined with cis-diamminedichloroplatinum II on the SCCVII/St tumor and normal tissues of the C3H/KM mouse. Int J Radiat Oncol Biol Phys. 1987 Oct;13(10):1523–1532. doi: 10.1016/0360-3016(87)90320-8. [DOI] [PubMed] [Google Scholar]
  35. Travis E. L. The sequence of histological changes in mouse lungs after single doses of x-rays. Int J Radiat Oncol Biol Phys. 1980 Mar;6(3):345–347. doi: 10.1016/0360-3016(80)90145-5. [DOI] [PubMed] [Google Scholar]
  36. von der Maase H., Overgaard J., Vaeth M. Effect of cancer chemotherapeutic drugs on radiation-induced lung damage in mice. Radiother Oncol. 1986 Mar;5(3):245–257. doi: 10.1016/s0167-8140(86)80054-8. [DOI] [PubMed] [Google Scholar]

Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK

RESOURCES